WO2006004109A1 - リパーゼ阻害剤 - Google Patents
リパーゼ阻害剤 Download PDFInfo
- Publication number
- WO2006004109A1 WO2006004109A1 PCT/JP2005/012392 JP2005012392W WO2006004109A1 WO 2006004109 A1 WO2006004109 A1 WO 2006004109A1 JP 2005012392 W JP2005012392 W JP 2005012392W WO 2006004109 A1 WO2006004109 A1 WO 2006004109A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gallate
- lipase
- lipase inhibitor
- food
- epicatechin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
Definitions
- the present invention provides a lipase inhibitor containing proanthocyanidins derived from tea.
- Obesity is one of the most serious diseases in modern society, the main factor of which is fat overdose. Moreover, it is known that excessive intake of fat causes not only obesity but also diabetes, diabetes, hyperlipidemia, hypertension, arteriosclerosis and the like caused by obesity.
- the only appetite suppressant, Mazindol (registered trademark) has been approved in Japan as a treatment for obesity, but side effects such as roar, constipation, stomach discomfort, nausea and vomiting have been reported ( Clinical evaluation 1985; 13 (2): 419-459, clinical evaluation 1985; 13 (2): 46 to 515).
- plant-derived lipase-inhibiting active substances have recently attracted attention, and in particular, polyphenols having lipase-inhibiting activity are derived from plant bark-derived tannin (Japanese Patent Publication No. 60-11912), leguminous plant power wallakeme Tannins and flavonoids and their glycosides contained in food (Japanese Patent Laid-Open No. 8-259557), lipid absorption-suppressing foods containing the main ingredients of green tea, epicarocatechin gallate and epicatechin gallate (Japanese Patent Laid-Open No.
- Lipase inhibitors consisting of water extracts such as bell pepper, shimeji mushroom, pumpkin, maitake, hijiki, green tea, oolong tea, etc. (JP-A-3-219872), flavones and flavonols (JP-A-7-61927) hydroxybenzoic acids (Gallic acid) (JP-A 1-102022), triterpene compounds and derivatives thereof (JP-A 9-40689), tamarind procyanidins as active ingredients Anti-obesity agents (Japanese Patent Publication No.
- Patent Document 1 JP-B-60-11912
- Patent Document 2 JP-A-8259557
- Patent Document 3 JP-A-3-228664
- Patent Document 4 JP-A-3-219872
- Patent Document 5 JP-A-7-61927
- Patent Document 6 Japanese Unexamined Patent Publication No. 1-102022
- Patent Document 7 JP-A-9-40689
- Patent Document 8 JP-A-9-291039
- Non-patent document 1 Summary of the 1999 National Nutrition Survey by the Ministry of Health, Labor and Welfare
- Non-Patent Document 2 Clinical Nutrition 2001; 98 (5): 577-588
- Non-Patent Document 3 Clinical Evaluation 1985; 13 (2): 419-459, Clinical Evaluation 1985; 13 (2): 461-515
- Non-Patent Document 4 Lancet 1998; 352: 67-172
- Non-Patent Document 5 J. Nutr. 1988; 128: 56-60, 1988
- Non-Patent Document 6 Japanese Clinical Journal of Food Science 1999; 52 (2): 71-77
- Non-Patent Document 7 Health and Nutrition Food Research 2002; 5 (3): 131-144
- Non-Patent Document 8 J. Am. Coll. Nutr. 2000; 19 (6): 789-796
- Non-Patent Document 9 Clin. Chim. Acta. 2001; 11 (2): 109-117
- Non-Patent Document 10 Nutrition 2003; 19 (10): 876-879
- Non-Patent Document 11 J. Nutr. 2002; 132: 1819-1824
- Non-Patent Document 12 Int. J. Obes. 1999; 23: 98-105
- Non-Patent Document 13 Japanese Nutrition ⁇ Journal of Food Science 1991; 44 (4): 251-259
- Non-Patent Document 14 Journal of Japanese Society of Clinical Nutrition 1998; 20 (1): 83-90
- Non-Patent Document 15 Chem. Pharm. Bull 1983; 31 (11): 3906-3914
- Non-Patent Document 16 Chem. Pharm. Bull 1989; 37 (1): 77-85
- the present invention provides a lipase inhibitor containing at least one proanthocyanidins originating from tea, focusing on components contained in tea with high palatability.
- the present invention further provides foods and drinks to which the above lipase inhibitor is added, have high palatability, and aim to reduce neutral fat in blood clots and promote health.
- the present invention further provides a pharmaceutical composition comprising the lipase inhibitor, which suppresses the absorption of diet-derived fat and suppresses an increase in blood neutral fat.
- the lipase inhibitor of the present invention has the following formula:
- the proanthocyanidins of the present invention are obtained from natural materials such as commercially available green tea, black tea, oolong tea, and the like, for example, Chem. Pharm. Bull. 1983; 31 (11): 3906-3914, 1983 or Chem. Pharm. Bull. 1989; 37 (1): 77-85.
- Lipase inhibitor The proanthocyanidins of the present invention can be used alone as a lipase inhibitor without containing other components, or can be used as a lipase inhibitor together with a solvent or a solid carrier.
- the solvent or carrier is preferably one that can be safely used as a food or medicine in consideration of the use as the following food and drink and / or medicine.
- the lipase inhibitor of the present invention has various uses, and examples thereof include use as an active ingredient in foods and pharmaceuticals for testing and research, preventing the accumulation of neutral fat. Lipase ⁇ . Harm ⁇ Cattle measurement method
- the lipase inhibitor of the present invention has a strong inhibitory action on lipases, particularly knee lipases.
- the inhibitory activity can be measured by the method specifically described in Example 1.
- a lipase inhibitor containing the proanthocyanidins of the present invention is added to food and drink as a lipase inhibitory active ingredient to prevent an undesired increase in blood neutral fat accompanying intake of fat in dietary power, And / or elevated blood neutral fat can be reduced.
- the food and drink are food and drink taken on a daily basis, for example, green tea, barley tea, oolong tea, black tea, coffee, sports drink, drinking water, seasoning, and dressing.
- drinks and drinks are usually soft drinks, cocktails, beer, whiskey, shochu, wine, sake, seasonings, dressing, seasoned rice, processed foods, instant foods, lemonade foods, chocolate, raw Creams, pastries, dairy products, health foods, supplements, etc.
- the amount of the lipase inhibitor of the present invention added to food and drink is added so that the intake of proanthocyanidins per meal is 0.1 mg to 10 g.
- the proanthocyanidins of the present invention are derived from food, there is no substantial upper limit to the amount added to foods and beverages that are very safe.
- the lipase inhibitor containing the proanthocyanidins of the present invention is an active ingredient of a drug for suppressing the absorption of diet-derived fat, preventing and increasing Z of blood neutral fat, and lowering it.
- a drug for suppressing the absorption of diet-derived fat, preventing and increasing Z of blood neutral fat, and lowering it can also be used.
- Preferred drugs are those that are administered orally, such as drinks lj, tablets, capsules, granules, powders, candy, drops Agents and the like.
- the amount of the compound of the present invention contained in the drug is 0.1 mg to 10 g per single dose
- the pharmaceutical product of the present invention is safe even if it is taken for a long time because the lipase-inhibiting component is highly safe. Therefore, it can be taken on a daily basis to prevent or eliminate obesity as a lifestyle-related disease.
- the purpose of the present invention is to add a lipase inhibitor containing at least one proanthocyanidins derived from tea leaves, and to have high palatability without sacrificing flavor, to reduce neutral fat, and to promote health. Can be provided.
- beverages with enhanced active ingredients obtained from tea that should be taken with meals are significant.
- by enhancing these ingredients it has become possible to develop tea that can reduce neutral fat.
- FIG. 1 shows the chemical structural formula of the compound subjected to the evaluation of lipase inhibitory activity in Example 2.
- the lipase activity was measured by using the fluorescent 4-methylumbelliferone oleate (4-UMO) as the substrate and measuring the fluorescence of the 4-methylumbelliferone produced by the reaction. Carried out.
- the buffer solution was 13 mM Tris-HCl (p) containing 150 mM NaCl and 1.36 mM CaCl.
- the substrate 4-UMO manufactured by Sigma
- the lipase was porcine lipase (manufactured by Sigma) in the same manner. What was prepared as a 400 U / ml solution using the above buffer solution was subjected to enzyme measurement.
- the enzyme reaction is 25. Under C condition, add 50 ⁇ l 4-UMO buffer solution and 25 ⁇ l distilled water (or sample aqueous solution) to 96-well microplate, mix, then add 25 ⁇ l lipase buffer solution To get started. After reacting for 30 minutes, 100 ⁇ 0.1M citrate buffer ( ⁇ 4.2) was added to stop the reaction, and it was generated by the reaction. The fluorescence (excitation wavelength: 355 nm, fluorescence wavelength: 460 nm) of the 4-methylumbelliferone was measured using a fluorescence plate reader (Fluoroskan Asent CF manufactured by Labsystems).
- the inhibitory activity of the test sample was determined as the amount of sample I C ( ⁇ ) that gave 50% inhibition over the activity of the control (distilled water).
- Control compounds catechin (5), epicatechin (1), gallocatechin (7), epigallocatechin (3), force techin gallate (6), epicatechin gallate (2), gallocatechin gallate (8), epigallocatechin gallate ( 4) was purchased from Wako Pure Chemical Industries, Ltd.
- proanthocyanidins of the present invention were obtained by the method described in the following paper. Chem. Pharm.
- proanthocyanidins those having a gallate group in the structure, in particular, a dimer containing an EGCG unit, has been found to have stronger activity and lipase inhibitory activity than EGCG itself.
- procyanrdin B-2 (9) 7.958 procyantdrn B-3 (1) 2.941 prodelphinidin A one 2 3 'one O-gallate (1 1) 0.171 prodelphinidin B-2 (12) 2.951 prodelphinidin B-2 3 -O-gallate (13 ) 1.969 prodelphinidin B-2 3,3'-di-0-ga1late (14) 0.107 prodelp injdin B-4 (15) 6.230 prodelphinidin B—4 3 -O-gallate (16) 0.223 prodelphinidin B-5 3,3 ' —Di— 0-gallate (17) 0.558
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Tea And Coffee (AREA)
- Non-Alcoholic Beverages (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/631,486 US20080306284A1 (en) | 2004-07-05 | 2005-07-05 | Lipase Inhibitors |
EP05758202A EP1767205A4 (en) | 2004-07-05 | 2005-07-05 | INHIBITORS OF LIPASE |
CN2005800222650A CN1980656B (zh) | 2004-07-05 | 2005-07-05 | 脂肪酶抑制剂的新制药用途 |
HK07111745.8A HK1103645A1 (en) | 2004-07-05 | 2007-10-31 | New pharmaceutical uses of the lipase inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004198303A JP2006016367A (ja) | 2004-07-05 | 2004-07-05 | リパーゼ阻害剤 |
JP2004-198303 | 2004-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006004109A1 true WO2006004109A1 (ja) | 2006-01-12 |
Family
ID=35782908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/012392 WO2006004109A1 (ja) | 2004-07-05 | 2005-07-05 | リパーゼ阻害剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080306284A1 (ja) |
EP (1) | EP1767205A4 (ja) |
JP (1) | JP2006016367A (ja) |
KR (1) | KR20070050433A (ja) |
CN (1) | CN1980656B (ja) |
HK (1) | HK1103645A1 (ja) |
TW (1) | TW200604189A (ja) |
WO (1) | WO2006004109A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008018638A1 (fr) * | 2006-08-11 | 2008-02-14 | Kracie Foods, Ltd. | Inhibiteur d'absorption de graisse et aliment et boisson utilisant celui-ci |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200637542A (en) * | 2004-12-22 | 2006-11-01 | Kikkoman Corp | Lipase inhibitor, preventing and treating agent of skin disease |
WO2006075638A1 (ja) * | 2005-01-14 | 2006-07-20 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ヘテロアリール誘導体 |
JP5290558B2 (ja) * | 2007-10-10 | 2013-09-18 | 株式会社エヌ・ティー・エイチ | ナチュラルヘナ抽出物とその用途 |
JPWO2010038842A1 (ja) * | 2008-10-01 | 2012-03-01 | 味の素株式会社 | 新規ポリフェノール化合物 |
JP2010143832A (ja) * | 2008-12-16 | 2010-07-01 | Suntory Holdings Ltd | リパーゼ阻害剤 |
WO2010073404A1 (ja) | 2008-12-26 | 2010-07-01 | 株式会社ニチレイバイオサイエンス | カシューアップルのプロアントシアニジン、プロアントシアニジン含有組成物、およびその用途 |
JP6211380B2 (ja) * | 2012-10-17 | 2017-10-11 | 丸善製薬株式会社 | Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤 |
JP6353034B2 (ja) * | 2014-04-23 | 2018-07-04 | 日本製紙株式会社 | 糖尿病予防または改善剤 |
CN105646450A (zh) * | 2014-12-02 | 2016-06-08 | 重庆宁牧生态农业有限公司 | 一种用作抗肥胖剂的化合物 |
WO2023112973A1 (ja) * | 2021-12-14 | 2023-06-22 | シード医療製薬株式会社 | プロアントシアニジンを含む脂質異常症改善剤並びに同脂質異常症改善剤を含む機能性食品、医薬部外品及び医薬品 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03228664A (ja) * | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6116982A (ja) * | 1984-07-03 | 1986-01-24 | Kikkoman Corp | 抗酸化剤 |
JPS6490131A (en) * | 1987-09-30 | 1989-04-06 | Shiseido Co Ltd | Lipase inhibitor |
JPH01102022A (ja) * | 1987-10-14 | 1989-04-19 | Advance Co Ltd | 肥満予防剤 |
JP3018013B2 (ja) * | 1989-10-19 | 2000-03-13 | 三井農林株式会社 | α―アミラーゼ活性阻害剤 |
JPH03219872A (ja) * | 1990-01-25 | 1991-09-27 | Meiji Seika Kaisha Ltd | リパーゼ阻害剤 |
JPH0517352A (ja) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
FR2699819B1 (fr) * | 1992-12-28 | 1995-02-24 | Dolisos Lab | Utilisation de prodelphinidines pour l'obtention de médicaments destinés au traitement de l'arthrose. |
JP2598873B2 (ja) * | 1993-08-25 | 1997-04-09 | 株式会社ロッテ | リパーゼ阻害剤およびこれを添加した飲食品 |
FI955691A (fi) * | 1994-11-28 | 1996-05-29 | Suntory Ltd | Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet |
JPH09291039A (ja) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | プロシアニジンを有効成分とする抗肥満剤 |
US6294190B1 (en) * | 1995-12-26 | 2001-09-25 | Suntory Limited | Antiobestic agent containing procyanidin as the active ingredient |
JPH09227398A (ja) * | 1996-02-20 | 1997-09-02 | Zeria Pharmaceut Co Ltd | 抗肥満剤 |
JPH09322710A (ja) * | 1996-06-03 | 1997-12-16 | Minato Seiyaku Kk | カテキン類を含有する茶抽出物の製造方法 |
FR2788438B1 (fr) * | 1999-01-14 | 2003-10-03 | Arkopharma Laboratoires | Composition pour le traitement de l'obesite et procede de traitement esthetique |
FR2790645B1 (fr) * | 1999-03-12 | 2001-06-08 | Arkopharma Laboratoires | Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols |
US6685970B1 (en) * | 1999-09-21 | 2004-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
AU2001251610A1 (en) * | 2000-04-13 | 2001-11-07 | Ocean Spray Cranberries, Inc. | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor |
US20040115285A1 (en) * | 2002-12-13 | 2004-06-17 | Peter Rohdewald | Method of normalizing glucose levels in blood of patients with diabetes mellitus by oral administration of proanthocyanidins containing plant extracts |
JP2008502691A (ja) * | 2004-06-14 | 2008-01-31 | マーズ インコーポレイテッド | 二量体ジガレートの組成物および使用方法 |
-
2004
- 2004-07-05 JP JP2004198303A patent/JP2006016367A/ja active Pending
-
2005
- 2005-07-05 TW TW094122724A patent/TW200604189A/zh unknown
- 2005-07-05 EP EP05758202A patent/EP1767205A4/en not_active Withdrawn
- 2005-07-05 KR KR1020077002625A patent/KR20070050433A/ko not_active Application Discontinuation
- 2005-07-05 WO PCT/JP2005/012392 patent/WO2006004109A1/ja active Application Filing
- 2005-07-05 CN CN2005800222650A patent/CN1980656B/zh not_active Expired - Fee Related
- 2005-07-05 US US11/631,486 patent/US20080306284A1/en not_active Abandoned
-
2007
- 2007-10-31 HK HK07111745.8A patent/HK1103645A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03228664A (ja) * | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
Non-Patent Citations (2)
Title |
---|
HATANO T. ET AL: "Flavan dimers with lipase inhibitory activity from Cassia nomame", PHYTOCHEMISTRY, vol. 46, no. 5, 1997, pages 893 - 900, XP004293498 * |
See also references of EP1767205A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008018638A1 (fr) * | 2006-08-11 | 2008-02-14 | Kracie Foods, Ltd. | Inhibiteur d'absorption de graisse et aliment et boisson utilisant celui-ci |
JP5177676B2 (ja) * | 2006-08-11 | 2013-04-03 | クラシエフーズ株式会社 | 脂肪吸収抑制剤及びそれを用いた飲食品 |
Also Published As
Publication number | Publication date |
---|---|
US20080306284A1 (en) | 2008-12-11 |
JP2006016367A (ja) | 2006-01-19 |
CN1980656A (zh) | 2007-06-13 |
EP1767205A4 (en) | 2010-02-10 |
KR20070050433A (ko) | 2007-05-15 |
CN1980656B (zh) | 2012-09-05 |
TW200604189A (en) | 2006-02-01 |
EP1767205A1 (en) | 2007-03-28 |
HK1103645A1 (en) | 2007-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5498471B2 (ja) | リパーゼ阻害剤 | |
JP5009619B2 (ja) | リパーゼ阻害剤 | |
WO2006004109A1 (ja) | リパーゼ阻害剤 | |
US7754695B2 (en) | Lipase inhibitors | |
WO2005116005A1 (ja) | リパーゼ阻害活性および/または抗酸化活性を有するエピガロカテキン二量体および三量体 | |
KR101342288B1 (ko) | 리파아제 저해 활성을 갖는 신규 화합물 | |
JP2010143832A (ja) | リパーゼ阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580022265.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500039 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11631486 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005758202 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077002625 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 510/CHENP/2007 Country of ref document: IN Ref document number: 1200700252 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005758202 Country of ref document: EP |